The startup develops an antibody-drug conjugate (ADC) specifically targeting lung cancer cells that over-express the FGFR1 protein. This approach aims to provide more effective treatment options for patients suffering from this aggressive form of cancer.
Funding
Funding not disclosed
Founders
Product
Problem
Lung cancer patients with tumors that overexpress the FGFR1 protein often face poor prognoses due to limited treatment options and the aggressive nature of the disease. Current therapies may lack the specificity needed to target cancer cells effectively, leading to systemic toxicity and reduced efficacy.
Solution
This startup is developing an antibody-drug conjugate (ADC) designed to selectively target and eliminate lung cancer cells that overexpress the FGFR1 protein. The ADC comprises a monoclonal antibody that binds specifically to FGFR1 on the surface of cancer cells, linked to a potent cytotoxic drug. Upon binding, the ADC is internalized into the cancer cell, where the drug is released, inducing cell death. This targeted approach aims to minimize damage to healthy tissues, potentially reducing side effects and improving patient outcomes compared to traditional chemotherapy.
Target Audience
The primary target audience includes oncologists specializing in lung cancer treatment and patients with FGFR1-positive non-small cell lung cancer (NSCLC).
Features
- Monoclonal antibody with high affinity and specificity for the FGFR1 protein
- Proprietary linker technology to ensure stable drug conjugation and controlled release
- Potent cytotoxic payload effective against lung cancer cells
- Demonstrated in vitro and in vivo efficacy in preclinical models